Successful conclusion of the Third World Local Production Forum in Abu Dhabi
Held under the theme 'Advancing Local Production for Health Equity, Global Health Security and Sustainable Development', the three-day forum took place from April 7 to 9, 2025, and witnessed the participation of top government officials, pharmaceutical and healthcare industry leaders, and stakeholders from across the world.
In his closing remarks, His Excellency Dr. Thani bin Ahmed Al Zeyoudi, Minister of State for Foreign Trade and Chairman of the Emirates Drug Establishment (EDE), reaffirmed the UAE's commitment to advancing local pharmaceutical production. He emphasized that the UAE is rapidly solidifying its position as a leading global hub for pharmaceutical innovation and advanced healthcare technologies, noting that local production has become not only a healthcare priority but also a strategic development imperative.
'We are pleased to host this global forum in partnership with the World Health Organization, reflecting the UAE's deep commitment to expanding local manufacturing capabilities, supporting research and development systems, and maintaining the highest quality standards in the production and distribution of medical products,' His Excellency stated.
He added, 'Our National Strategy for Advanced Innovation enables us to integrate modern technologies such as artificial intelligence, big data, and smart manufacturing into all stages of healthcare production, while maintaining our commitment to environmental sustainability.'
Concluding his address, H.E stressed the importance of purposeful international cooperation, stating, 'Through this forum, we affirm that international collaboration is the path to constructive change. By linking investment to innovation and policy to impact, we can build a more inclusive and resilient healthcare system that serves communities everywhere.'
Her Excellency Dr. Fatima Al Kaabi, Director General of Emirates Drug Establishment (EDE), also delivered remarks during the forum, underscoring that the UAE is leading by example in building resilient and innovative pharmaceutical ecosystems capable of addressing evolving healthcare needs. 'Hosting the World Local Production Forum is a testament to the UAE's progress in the pharmaceutical manufacturing sector,' she said. 'We believe that investing in local capabilities is the cornerstone for ensuring health security and equitable access to essential treatments.'
Dr. Yukiko Nakatani, Assistant Director General for Access to Medicines and Health Products Division at the World Health Organization, highlighted the global relevance of the forum, stating, 'This forum comes at a critical time as health systems worldwide face growing challenges in ensuring timely and equitable access to essential health products. Strengthening local production is a foundational pillar for building more resilient healthcare systems, and the UAE provides a good example with holistic approach for other countries and regions.'
The forum featured a robust program of discussions across eight key thematic areas, including policies and regulatory frameworks for strengthening local production systems; innovative strategies for financing and investment; the promotion of research, innovation, and technology transfer across the pharmaceutical value chain; and pandemic preparedness through expanded manufacturing capacity, demand forecasting, and emergency financing.
Additional themes included the integration of artificial intelligence, digital transformation, and climate adaptation in transforming local manufacturing; the formation of strategic partnerships to support sustainable local production and epidemic preparedness; knowledge sharing through case studies of successful country-level initiatives; and the CEO Forum, which convened global executives to explore the pharmaceutical industry's role in shaping public health outcomes.
Her Excellency Dr. Al Kaabi also participated in a high-level panel titled 'Localizing Pharmaceutical Innovation', which brought together members of the PharmaGroup, representing 29 global pharmaceutical companies, and the Mycomed Association, which includes around 70 companies in the medical device and equipment sectors. During the session, Dr. Al Kaabi presented the vision of the Emirates Drug Establishment (EDE) to position the UAE as a global center for pharmaceutical innovation through the attraction of top talent, advanced technologies, and investment into the sector. She emphasized the role of pharmaceutical manufacturing in supporting economic diversification, knowledge economy transformation, and long-term healthcare system resilience.
Dr. Ashraf Malak and Dr. Dederick Koh, also speaking at the forum, highlighted the Pharmage Association's 20-year legacy in the UAE and its contributions to the availability of modern and innovative treatments. They commended the Emirates Drug Establishment (EDE) for its role in shaping a forward-thinking regulatory and industrial environment that is achieving tangible impact across the sector.
In another panel session, global health leaders explored the future of equitable access to medicines, regional manufacturing, innovation ecosystems, and pandemic preparedness.
Dr. Luis Pizarro, Executive Director, Drugs for Neglected Diseases initiative (DNDi) addressed the importance of health equity and the moral imperative to focus on neglected populations and diseases. He reflected on DNDi's work in building collaborative R&D platforms and promoting affordable access to life-saving treatments. 'The innovation ecosystem must serve those most in need. That means patients in the most vulnerable contexts must be central to our R&D agendas,' he emphasized. He mentioned strategies for strengthening local capacities to make local production a reality. First, he highlighted the importance of not just discussing technology transfer, but ensuring that countries also possess the necessary technological know-how to implement and sustain it. 'We cannot speak about technology transfer without ensuring the know-how is in place,' he said. Secondly, he stressed the need to invest in human capital—developing local expertise and skills to drive innovation and production. Finally, he called for the design of health solutions that are relevant to the needs of local populations, underscoring the importance of defining a target product profile that aligns with regional contexts and public health demands.
Dr. Asma Ibrahim Al Mannaei, Executive Director, Research and Innovation Center, Department of Health – Abu Dhabi presented Abu Dhabi's strategic vision for health innovation, emphasizing the Emirate's commitment to becoming a regional leader in research and development, clinical trials, and health technology advancement. 'Our vision is to position Abu Dhabi as a hub for health innovation in the region,' she affirmed. Dr. Al Mannaei highlighted a range of forward-looking initiatives, regulatory modernization, and the adoption of data-driven health solutions. She also emphasised the UAE's exemplary performance during the COVID-19 pandemic, noting that Abu Dhabi was ranked the number one most resilient city in pandemic crisis management. This success, she said, was achieved through strong collaboration between local and international entities, transforming the Emirate into a logistics and solutions hub for the region. Through these coordinated efforts, the UAE facilitated the delivery and management of over 260 million doses of vaccines to countries in need, showcasing its global solidarity and logistical excellence. She stated the importance of R&D and local production to ensure long-term sustainability and self-reliance in health systems, ultimately safeguarding the region.
Mr. Robert Matiru, Director of Programmes at UNITAID, emphasized the importance of moving beyond rhetoric to showcase tangible partnerships that have advanced local production capacity for equitable access to health tools. Highlighting the benefit of collaborations, Matiru explained how UNITAID structured a partnership that brought together critical resources. A catalytic $10 million investment—modest in scale but significant in impact—was mobilized under the Access to COVID-19 Tools (ACT) Accelerator. This funding enabled partnerships with diagnostic manufacturers in the UK (Mologic, now Global Access Diagnostics) and South Korea (Bionote), facilitating rapid technology transfer and know-how sharing. With this support, IPD developed the capacity to manufacture lateral flow COVID-19 rapid tests, meeting global regulatory and quality standards. Before this initiative, Africa imported approximately 90% of its rapid tests—amounting to over half a billion tests annually for diseases like HIV and malaria. This collaboration helped shift the paradigm: IPD expanded its production capacity to 75 million rapid tests per year, significantly enhancing self-reliance in diagnostics. 'This is a prime example of how thoughtful, well-structured partnerships—combining financing, technology transfer, and strategic market planning—can empower local manufacturers to play a key role in global health security,' Matiru concluded.
Mr. Rajinder Kumar Suri, CEO, Developing Countries Vaccine Manufacturers Network (DCVMN) shed light on the indispensable role of developing countries' vaccine manufacturers in pandemic response and preparedness. He discussed the lessons learned from COVID-19 and how vaccine equity was undermined by global supply chain gaps and overreliance on a few manufacturers. 'We cannot afford to repeat the mistakes of the past. Strengthening regional manufacturing hubs, especially in the Global South, is critical for timely access during future pandemics,' Mr. Suri stated. He advocated for technology transfer mechanisms, better regulatory alignment, and long-term funding strategies that empower regional players.
Mr. Guilherme Cintra, Head of Policy, Coalition for Epidemic Preparedness Innovations (CEPI) shared CEPI's vision for advancing equitable vaccine development and distribution in the face of future health emergencies. He highlighted CEPI's commitment to building robust, end-to-end R&D ecosystems that span from early-stage innovation to large-scale delivery. Underscoring the importance of collaboration, he stated, 'The concept of self-reliance is an illusion—we need to depend and help each other.' He emphasized the need for inclusive, cooperative approaches where regional stakeholders are not merely recipients but active contributors within global innovation pipelines, ensuring that solutions are shaped by and for the communities they serve.
As part of her engagements during the forum, Her Excellency Dr. Fatima Al Kaabi, conducted a visit to the Adcan Pharma manufacturing facility. During the meeting with the factory's management, both parties explored avenues for enhanced coordination and collaboration aimed at supporting the growth and sustainability of the local pharmaceutical manufacturing ecosystem. The discussions focused on reinforcing national capabilities and fostering innovation across the production value chain.
The third edition of the World Local Production Forum received comprehensive support from the Emirates Drug Establishment, in close cooperation with the World Health Organization and a broad network of international partners. It served as a dynamic platform for government leaders, policymakers, investors, and industry experts to address critical issues related to sustainable local production and global health security.
Key outcomes from this Forum included 4077 participants from 141 countries, 16 ministers and Engagement of over 229 international speakers representing government agencies, health institutions, regulatory bodies, and the private sector.
This reinforced the UAE's steadfast commitment to fostering global partnerships that accelerate local production capacities, ensuring equitable access to healthcare solutions worldwide. It also highlighted the country's growing prominence as a global hub for life sciences, pharmaceutical innovation, and advanced health technologies.
In a symbolic gesture marking the end of the forum, the hosting torch was officially handed over to the Republic of Indonesia, which will host the fourth edition of the World Local Production Forum in 2026. This transition reflects the spirit of international cooperation and continued momentum toward achieving inclusive, resilient, and sustainable health systems across the globe.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Khaleej Times
2 hours ago
- Khaleej Times
UAE: 10k steps a day? New study says 7,000 is more realistic to cut chronic disease risk
Walking approximately 7,000 steps per day can significantly lower the risk of chronic diseases, cognitive decline, and even premature death, according to a new global study — an encouraging insight for UAE residents looking to improve their health. Published by the Lancet Public Health Journal, the study analysed data from over 160,000 adults. It suggested that 7,000 steps may be a more realistic and achievable target than the widely promoted, but unofficial, 10,000-step target — especially for those with low levels of physical activity. 'It is important to not completely dismiss the 10,000 steps. Note that risk continues to decrease beyond 7,000 steps for some outcomes. However, the rate at which it reduces risk starts to decrease," Melody Ding, associate professor at the Sydney School of Public Health, told Khaleej Times. "Therefore, there is a 'return on investment' with every additional 1,000 steps taken,' she added. She emphasised that active individuals who are already hitting the 10,000-step mark should continue with their routine. 'However, for those of us who are far from achieving the 10,000 targets, getting to 7,000 steps per day offers almost comparable health benefits for the outcomes we examined," she explained. This is particularly relevant in the UAE, where sedentary lifestyles and high fast food consumption have contributed to one of the world's highest obesity rates — one of the major causes of chronic diseases. This trend is likely to continue in the coming years. As reported by Khaleej Times, a Lancet study earlier said that the number of people in the UAE suffering from obesity — both males and females — will see a significant increase over the next two-and-a-half decades. It predicted that overweight and obesity prevalence among adult males in the UAE aged 25-plus will increase from 84 per cent in 2021 to 94 per cent in 2050, the highest globally, along with Kuwait and a few other countries. Unlike earlier studies that mainly focused on heart health or overall death rates, the Lancet Public Health journal said this is the first study to comprehensively examine how taking more steps per day can reduce the risk of several different health outcomes. Compared to 2,000 steps per day, the study revealed that walking approximately 7,000 steps can reduce all-cause mortality by 47 per cent, cardiovascular disease by 25 per cent, cancer by six per cent, type 2 diabetes by 14 per cent, dementia by 38 per cent, depression by 22 per cent and falls by 28 per cent. The study also revealed that even modest step counts of around 2,000 steps per day are linked to better health compared to very low activity.
The National
2 days ago
- The National
Pictures of the week: From an aid ship leaving Abu Dhabi for Gaza to an equestrian stunt in Kyrgyzstan
It is among the greatest health debates of our time; splashed across newspapers with contradicting headlines - is coffee good for you or not? Depending on what you read, it is either a cancer-causing, sleep-depriving, stomach ulcer-inducing black death or the secret to long life, cutting the chance of stroke, diabetes and cancer. The latest research - a study of 8,412 people across the UK who each underwent an MRI heart scan - is intended to put to bed (caffeine allowing) conflicting reports of the pros and cons of consumption. The study, funded by the British Heart Foundation, contradicted previous findings that it stiffens arteries, putting pressure on the heart and increasing the likelihood of a heart attack or stroke, leading to warnings to cut down. Numerous studies have recognised the benefits of coffee in cutting oral and esophageal cancer, the risk of a stroke and cirrhosis of the liver. The benefits are often linked to biologically active compounds including caffeine, flavonoids, lignans, and other polyphenols, which benefit the body. These and othetr coffee compounds regulate genes involved in DNA repair, have anti-inflammatory properties and are associated with lower risk of insulin resistance, which is linked to type-2 diabetes. But as doctors warn, too much of anything is inadvisable. The British Heart Foundation found the heaviest coffee drinkers in the study were most likely to be men who smoked and drank alcohol regularly. Excessive amounts of coffee also unsettle the stomach causing or contributing to stomach ulcers. It also stains the teeth over time, hampers absorption of minerals and vitamins like zinc and iron. It also raises blood pressure, which is largely problematic for people with existing conditions. So the heaviest drinkers of the black stuff - some in the study had up to 25 cups per day - may want to rein it in. Rory Reynolds
Zawya
3 days ago
- Zawya
Rainy season increases cholera threat in South Sudan
The ongoing rainy season in South Sudan is slowing cholera response efforts in some locations, raising concerns about further transmission and undermining progress the country has made so far in combating the outbreak. South Sudan experiences heavy rainfall between mid-July and October. The States of Jonglei, Unity, Upper Nile, Northern Bhar el Ghazal, Warrap, parts of Central Equatoria, and others experience seasonal flooding, resulting in massive displacement, and affecting the delivery of basic health services. The rainy season worsens access and sanitation, disrupts the shipment of medical supplies, hinders deployment of rapid response teams, and vaccination impedes efforts, making it difficult to protect communities and save lives. The country declared a cholera outbreak in October 2024, since then, the Ministry of Health with support from World Health Organization (WHO) and other partners, has mounted a comprehensive response, including deployment of rapid response teams, prepositioning medical supplies and coordination efforts across all levels to protect communities and safe lives. This is the longest cholera outbreak in the country's history, since independent in September 2011. As of 30 June 2025, South Sudan has reported a cumulative total of 77 555 suspected cases and 1 401 deaths these cases have been reported from 55 counties, across 9 States and all 3 Administrative areas. A cumulative total of 11 554 tested positive using the rapid diagnostic test kits (RDT), and an additional 424 cases had laboratory isolation of Vibrio Cholera. In response, the country has successfully conducted an oral cholera vaccination campaign, reaching over 6.9 million people in 40 Counties. affected counties, these campaigns have significantly slowed the spread of the outbreak and is estimated to have saved hundreds of lives with a total of 19,987 deaths averted. To support vaccination efforts, South Sudan secured over 8.7 million doses of oral cholera vaccines from the International Coordination Group (ICG) to protect communities, and deployment. the country has applied for additional doses. WHO has played a critical role by training over 2000 health workers and community members on various aspects of the response including case management, risk communication and community engagement, IPC/WASH, vaccination and surveillance. The organization has also supported establishment of 102 oral rehydration points (ORPs), 88 cholera treatment units. (CTUs) and 19 cholera treatment centers (CTCs) through implementing partners, which have significantly reduced fatalities. Over 175 Metric Tons of medical supplies have been distributed across the affected Counties. Additionally, WHO has conducted extensive water quality testing and provided treatment to the affected communities. Several factors have contributed to the outbreak, including high population density, population movement, limited access to water and sanitation facilities, open defecation, and poor hygiene practices, created a highly vulnerable situation that led to imported cases and local transmission. Mr Kereni Gong, Acting Director General, Unity State Ministry of Health highlighted the urgent need for interventions in response to the ongoing flooding, emphasizing the importance of immediate action to save lives of the flooding and call for urgent interventions to save lives 'Unity state is the epicentre of the current cholera outbreak. With support from WHO and other partners The State Ministry of Health managed to bring down the number of cases, but we need more support as we enter the rainy season, during which cases have already begun to rise. We are also aware that floods are coming from the southern part of Unity State which will further worsen the situation' he said Dr Humphrey Karamagi, WHO Representative in South Sudan, underscored the gravity of the situation and express gratitude on the effectiveness of the ongoing cholera response efforts: 'The scale of the current outbreak is unprecedented, the onset of the rainy season poses significant challenge in addition to the prevailing humanitarian crises' said Dr Karamagi 'Under the leadership of the Ministry of Health we have been able to protect the communities by mounting effective response including vaccinating over 7 million people, now Is the time to up our game in strengthening case management, surveillance and coordination to save lives.' Additional funding is required to contain the outbreak, as the rainfall poses the risk of transmission., WHO requires additional funding to bolster current operations by deploying swift response teams to newly identified hotspots, maintaining essential health services for affected communities, and procuring, shipping, and distributing more emergency supplies to support the ongoing response. Distributed by APO Group on behalf of World Health Organization (WHO) - South Sudan.
